The Development of Primary Cutaneous Adenoid Cystic Carcinoma in a Patient with Ankylosing Spondylitis Treated with Etanercept

Cansu D. U., Kasifoglu T., Acikalin M. F., Korkmaz C.

SOUTHERN MEDICAL JOURNAL, cilt.102, sa.7, ss.738-740, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 102 Sayı: 7
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1097/smj.0b013e3181a7fb33
  • Dergi Adı: SOUTHERN MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.738-740
  • Anahtar Kelimeler: ankylosing spondylitis, cutaneous adenoid cystic carcinoma, etanercept, tumor necrosis factor alpha inhibitors, SQUAMOUS-CELL CARCINOMA, RHEUMATOID-ARTHRITIS, RAPID ONSET, THERAPY, RISK, CANCER
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

The tumor necrosis factor-alpha (TNF-alpha) inhibitors are widely used in the treatment of some autoimmune disorders with promising results. However, their safety has been questioned with multiple postmarketing reports of increased risk for malignancies. The case of a patient with ankylosing spondylitis who developed cutaneous adenoid cystic carcinoma after three years of treatment with anti-TNF-alpha therapy is discussed.